EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 4.0

Bimekizumab 2‐year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results

Raj Chovatiya iD, Afsaneh Alavi iD, Takuya Miyagawa iD, Irina Turchin iD, Thrasyvoulos Tzellos iD, Hessel H van der Zee iD, Christina Crater iD, Bartosz Lukowski iD, Nicola Tilt iD, Christos C Zouboulis iD

Journal of the European Academy of Dermatology and Venereology · 22.07.2026

DOI: 10.1111/jdv.70631 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 22.07.2026. Verfasst von Raj Chovatiya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rosalind Franklin University of Medicine and Science Chicago Medical School, North Chicago, Illinois, USA. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BE HEARD EXTHiSCRIHS4bimekizumabdisease durationhidradenitis suppurativa

Autor:innen und Institutionen

  • Rosalind Franklin University of Medicine and Science Chicago Medical School, North Chicago, Illinois, USA.
  • Center for Medical Dermatology + Immunology Research, Chicago, Illinois, USA.
  • Department of Dermatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
  • European Hidradenitis Suppurativa Foundation (EHSF) e.V, Dessau, Germany.
  • Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Brunswick Dermatology Center, Fredericton, New Brunswick, Canada.

ORCID-Profile: Raj Chovatiya, Afsaneh Alavi, Takuya Miyagawa, Irina Turchin, Thrasyvoulos Tzellos, Hessel H van der Zee, Christina Crater, Bartosz Lukowski, Nicola Tilt, Christos C Zouboulis

Zitieren

APA

Chovatiya, R., Alavi, A., Miyagawa, T., Turchin, I., Tzellos, T., van der Zee, H. H., Crater, C., Lukowski, B., Tilt, N., & Zouboulis, C. C. (2026). Bimekizumab 2‐year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70631

Vancouver

Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, et al. Bimekizumab 2‐year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70631

BibTeX
@article{Chovatiya2026,
  author = {Chovatiya, Raj and Alavi, Afsaneh and Miyagawa, Takuya and Turchin, Irina and Tzellos, Thrasyvoulos and van der Zee, Hessel H and Crater, Christina and Lukowski, Bartosz and Tilt, Nicola and Zouboulis, Christos C},
  title = {Bimekizumab 2‐year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70631}
}
Kostenlos starten →